- Research article
- Open Access
- Open Peer Review
Increased expression of collagens, transforming growth factor-β1, and -β3 in gluteal muscle contracture
© Zhao et al; licensee BioMed Central Ltd. 2010
- Received: 6 October 2009
- Accepted: 25 January 2010
- Published: 25 January 2010
Gluteal muscle contracture (GMC) is a multi-factor human chronic fibrotic disease of the gluteal muscle. Fibrotic tissue is characterized by excessive accumulation of collagen in the muscle's extracellular matrix. Transforming growth factor (TGF)-β1 and -β2 are thought to play an important role in fibrogenesis, while TGF-β3 is believed to have an anti-fibrotic function. We hypothesize that the expression of collagen and TGF-βs would be up-regulated in GMC patients.
The expression of collagen type I, type III and TGF-βs were studied in 23 fibrotic samples and 23 normal/control samples in GMC patients using immunohistochemistry, reverse transcription and polymerase chain reaction (RT-PCR) and western bolt analysis.
Compared to the unaffected adjacent muscle, increased expression of TGF-β1 and -β3 was associated with deposition of collagen type I and type III in the fibrotic muscle of the GMC patients at the mRNA level. Strong up-regulation of these proteins in fibrotic muscle was confirmed by immunohistochemical staining and western blot analysis. TGF-β2 was not up-regulated in relation to GMC.
This study confirmed our hypothesis that collagen types I, III, TGF-β1 and TGF-β3 were up-regulated in biopsy specimens obtained from patients with GMC. Complex interaction of TGF-β1 with profibrotic function and TGF-β3 with antifibrotic function may increase synthesis of collagens and thereby significantly contribute to the process of gluteal muscle scarring in patients with GMC.
- Collagen Type
- Fibrotic Disease
- Adjacent Muscle
- Contraction Band
- Gluteal Muscle Contracture
Gluteal muscle contracture (GMC) is a clinical syndrome with multiple etiologies, either congenital or acquired, GMC is not uncommon and exists worldwide [1–5]. Clinically, GMC progresses through distinct stages. The earliest stage is characterized by unnoticed difficulties in adducting the hip or squatting, and over time, it gives rise to serious functional disorders of the hip. Although abnormal scarring is a known phenomenon in the fibrotic muscle (contraction band) of GMC patients, the mechanism of this human chronic fibrotic muscle disorder is not known.
Transforming growth factor (TGF)-βs are members of a superfamily of polypeptides which play a key role in cell regulation, angiogenesis, embryo development, apoptosis induction, and wound healing [6–8]. Three isoforms of TGF-β are known to exist in mammals, namely TGF-β1, -β2, and -β3, each with distinct roles in wound repair. TGF-β1 and -β2 are potent profibrotic factors thought to be involved in the pathogenesis of many fibrotic diseases and are important in almost every step in the process of tissue fibrosis by simultaneously signaling fibroblasts to increase the synthesis of matrix proteins, decrease the production of matrix-degrading proteases, and increase the production of inhibitors of these proteases [9, 10]. Both in vitro and in vivo studies have revealed an over-expression of TGF-β1 and TGF-β2 in fibrotic lesions, and convincingly demonstrated that blocking the bioactivity of TGF-β1 and -β2 could suppress collagen production and subsequently could modulate the fibrotic process [11, 12]. In contrast, TGF-β3 reduces the fibrotic response. The exogenous addition of TGF-β3 peptide has an anti-scarring properties as well [13, 14].
Although fibrogenic roles for each of the three isoforms of TGF-βs have been documented during fibrosis in various tissues and organs, their roles in GMC patients are not known. This study was designed, therefore, with an expectation of finding an increased expression of collagen types I and III, and TGF-βs in this fibrotic disease of gluteal muscle.
Tissue specimens and antibodies
Between January 2007 and March 2008, 46 samples (23 contraction bands and 23 adjacent normal muscle samples) of GMC patients were enrolled in this study in the Department of Orthopaedic Surgery of The 2nd Affiliated Hospital of Medical College of Xi'an JiaoTong University. All our studies were permitted by the Ethical Board of The 2nd Affiliated Hospital of Medical College of Xi'an JiaoTong University and followed the Declaration of Helsinki Guidelines. Informed consent was obtained from all of the patients. All 23 patients (10 males and 13 females between the ages of 7 to 27 years, 8 years of course at least) were carried out with contraction band releasing surgery as we described before . Tissues used for RT-PCR and western blot analysis were immediately frozen in liquid nitrogen and stocked at -80°C. Mouse anti-human monoclonal antibodies against collagen types I and III were purchased from Abcam (Cambridge, UK), and mouse anti-human monoclonal antibodies against TGF-β1, -β2, and β-3 were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, US). Second antibody for immunohistochemical analyses (biotinylated goat anti-mouse IgG antibody) was obtained from Vector Laboratories (Burlingame, CA, USA).
Histology and immunohistochemistry
Tissue samples were fixed in 4% paraformaldehyde at 4°C for 24 hours. Paraffin sections (4 um) for histologic analysis were stained with hematoxylin/eosin, Masson trichrome, and picrosirius. For immunohistochemical analysis, paraffin sections were deparaffinized with xylene, rinsed thoroughly with ethanol, then soaked in 0.3% hydrogen peroxide in methanol to inactivate endogenous peroxidase activity. After mild treatment with 0.05% trypsin-EDTA, the sections were incubated with 10% goat serum to block non-specific protein binding. The blocked sections were incubated with antibodies against collagen types I and III (1:800), or antibodies against TGF-β1, -β2, and -β3 (1:200) at 4°C overnight. After incubation with the primary antibody, the sections were incubated with second antibody and alkaline phosphatase streptavidin (Vector Laboratories, Burlingame, CA, USA). The sections were stained using a Vector Red Alkaline Phosphatase Substrate Kit (Vector Laboratories) according to the manufacturer's instructions and counterstained with Mayer's hematoxylin. One section from each series was incubated with PBS as the first antibody as a negative control. The staining intensities of collagen types I and III, TGF-β1, -β2, and -β3 in the contraction band and unaffected adjacent muscle were graded semi-quantitatively using the following scale: (-) = no staining; (+) = weak staining; (++) = moderate staining; and (+++) = strong staining.
Reverse transcription and polymerase chain reaction (RT-PCR)
Synthetic gene-specific primer sequences for collagen types I and III and for TGF-β1, -β2, -β3 and β-actin
Collagen types I
Collagen type III
Western blot analysis
Tissue protein extracts were prepared using a modified RIPA buffer (50 mM Tris-HCl [pH 7.4], 1% NP-40, 150 mM NaCl, and 1 mM EDTA) supplemented with a cocktail of protease inhibitors (1 mM PMSF [1 μg/mL of aprotinin, leupeptin, and pepstatin]). Tissue was homogenized at 4°C and the resulting homogenate centrifuged for 12,000 rpm for 15 min at 4°C to remove cell debris. Sample protein concentrations were quantified using the BCA protein assay (Pierce, Rockford, IL, USA). Equivalent levels of protein (20 μg) were analyzed by SDS-PAGE and subsequently transferred to polyvinylidene difuoride (PVDF) membranes (Bio-Rad, Hercules, CA, USA). The membranes were than blocked with 10% fat-free skim milk powder in phosphate-buffered saline containing 0.1% Tween 20, and incubated with antibodies against TGF-β1, -β2, and TGF-β3 (1:400). After a series of brief PBST washes, the membranes were then incubated with the appropriate species-specific horseradish peroxidase-conjugated antibodies (1:5000; Jackson ImmunoResearch, West Grove, PA, USA). Antibody-specific bands were visualized using standard ECL chemiluminescence reagents (Pierce) and photographed. The density of each band was measured by densitometry. The relative expression of collagen types I and III, TGF-β1, -β2, and-β3 protein were normalized to the expression of the internal control (β-actin).
Densitometric measurement was performed using a GS-700 Imaging Densitometer with Multi-Analyst software (Bio-Rad). All values were expressed as the means ± SD. The paired T-test was used to examine differences between paired samples. Statistical analysis was performed using SPSS 13.0 software and P values < 0.05 were considered significant.
Expression of collagen types I and III is up-regulated in the contraction band
Semi-Quantitative Scale of Collagen Type I, Type III, TGF-β1, TGF-2 and TGF-β3 in Contraction Band and Adjacent Muscle
Collagen Type I
Collagen Type III
Expression of TGF-β1 and -β3 mRNA is up-regulated in the contraction band
As TGF-β1, -β2, and -β3 have a close relationship with the process of tissue fibrosis, we first examined the mRNA level in the contraction band by RT-PCR. The expression of TGF-β1 and -β3 was weakly detected in unaffected adjacent muscle, while the expression was increased in the contraction band (Fig. 2A; 5 representative cases are shown). Semi-quantitative densitometric analysis of the blots indicated that the levels of TGF-β1 and -β3 mRNA in the contraction band were increased 8.1 and 2.5-fold, respectively (Fig. 2B; mean of 23 cases; P < 0.01), relative to adjacent muscle in the same patients. The expression of TGF-β2 was not increased (P > 0.05).
Immunohistochemical staining for TGF-β1, -β2, and -β3
Expression of TGF-β1 and -β3 protein is up-regulated in the contraction band
Although enormous work has been done to investigate the mechanism of many fibrotic diseases, such as keloids, atherosclerosis, liver cirrhosis, lung fibrosis, and kidney fibrosis, the mechanism involved in this fibrotic muscle disease is not known [15–19]. In the current study, we detected the expression and localization of collagen types I and III, and TGF-βs in GMC patients by immunohistochemistry, RT-PCR, and western blot analysis.
Our first experiment demonstrated that collagen types I and III were major components of the contraction band and were remarkably elevated compared to unaffected adjacent muscle. Several reports have documented increased synthesis of extracellular matrix (ECM), including collagen type I, during development of fibrosis in experimental and human diseases. However, in terms of collagen type III, the status of synthesis is controversial. Indeed, some reports have suggested that synthesis is elevated and some have demonstrated that synthesis is unchanged . A possible explanation for this difference could be that cultured fibroblasts obtained from fibrotic lesions have lost specific characteristics. Type III collagen gene expression might be transiently activated in specific stages of development of fibrosis, while those of cultured fibroblasts might have been by chance those inactive in other stages, as supported by the work of Zhang .
TGF-βs are pluripotent growth factors and are highly conserved between species. There is 64%-85% amino acid sequence homology between TGF-βs. These TGF-βs isoforms bind to common specific transmembrane receptors (TGF-β receptor types I and II) to target genes via the SMAD family of signal transducing proteins . Previous studies have shown that TGF-βs play pivotal roles in the development of fibrosis in various tissues and organs [15–19]. Their role on transcriptional activation of collagen genes and post-translational modification makes them potential candidates to contribute in matrix remodeling during the fibrosis. Thus, we believe that the formation of GMC is due, at least in part, to an alteration of expression of the TGF-β family. In our study, we found that the mRNA expression of TGF-β1 and TGF-β3 is remarkably increased in contraction band compared with the expression in unaffected adjacent muscles. These observations were enhanced using immunohistochemistry and western blot analysis. From the results of our study, and taking into account the findings of previous studies, it is suggested that up-regulation of TGF-β1 and TGF-β3 in the contraction band in GMC patients contribute to muscle fibrosis. The results also suggest that the process of fibrosis in GMC patients might be a result of competition between the profibrotic function of TGF-β1 and the anti-fibrotic function of TGF-β3. Further study would be done to investigate whether TGF-β1-to-TGF-β3 ratio would influence progresses of fibrosis as some research reported .
However, in terms of TGF-β2, there was no evidence indicating a difference between the two kinds of tissues at the two levels. Previous studies have emphasized that TGF-β2 has a potential role in the formation of fibrosis, but the time window is not clear . From our findings in the experiments herein, we hypothesize that TGF-β2 is secreted only at the initial stage and might be an assistant factor for TGF-β1 in fibrosis in gluteal muscle in vivo.
Curiously, in the survey of our post-operative patients, most undergo another form of fibrosis (hypertrophic scars in skin or keloids in the incision site) which is in agreement with other reports [25, 26]. These patients seemingly have a tendency towards fibrosis in organs. Whether there is a healing-associated gene variation in these patients needs additional work for confirmation.
The present study confirmed our hypothesis that GMC is a fibrotic disease of gluteal muscle characterized by accumulation of collagen types I and III, and up-regulation of TGF-β1 and -β3. All of these findings could be important in understanding the molecular mechanism of GMC and could provide specific sites for molecular intervention for treatment or arrest of the progression of this disease.
We thank Mr Zeng-Tie Zhang for skillful technical assistance. This study was supported by a grant from The Food and Drug Administration of Shannxi Province (Y200 334002).
- Zhao CG, He XJ, Lu B: Classification of gluteal muscle contracture in children and outcome of different treatments. BMC Musculoskelet Disord. 2009, 10: 34-10.1186/1471-2474-10-34.View ArticlePubMedPubMed CentralGoogle Scholar
- Brignall CG, Brown RM, Stainsby GD: Fibrosis of the gluteus maximus as cause of snapping hip - A case-report. Journal of Bone and Joint Surgery-American Volume. 1993, 75A: 909-910.Google Scholar
- Hnevkovsky O: Progressive fibrosis of the vastus intermedius muscle in children. A cause of limited knee flexion and elevation of the patella. Journal of Bone and Joint Surgery-British Volume. 1961, 43: 318-325.Google Scholar
- Motta A: La miosite fibrosa causa di limitazione articolare del ginocchion e dell'anca. Clin Ortop. 1971, 23: 114-121.Google Scholar
- Suksathien R: Idiopathic fibrosis of the quadriceps muscle: a case report with magnetic resonance imaging and pathological findings. J Med Assoc Thai. 2008, 91: 568-573.PubMedGoogle Scholar
- Border WA, Noble NA: Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994, 331: 1286-1292. 10.1056/NEJM199411103311907.View ArticlePubMedGoogle Scholar
- Massague J: The transforming growth factor-beta family. Annu Rev Cell Biol. 1990, 6: 597-641. 10.1146/annurev.cb.06.110190.003121.View ArticlePubMedGoogle Scholar
- Roberts AB, Sporn MB: Physiological actions and clinical applications of transforming growth factor-beta (TGF-beta). Growth Factors. 1993, 8: 1-9. 10.3109/08977199309029129.View ArticlePubMedGoogle Scholar
- Lee TY, Chin GS, Kim WJ: Expression of transforming growth factor beta 1, 2, and 3 proteins in keloids. Ann Plast Surg. 1999, 43: 179-184. 10.1097/00000637-199943020-00013.PubMedGoogle Scholar
- Colwell AS, Yun R, Krummel TM: Keratinocytes modulate fetal and postnatal fibroblast transforming growth factor-beta and Smad expression in co-culture. Plast Reconstr Surg. 2007, 119: 1440-1445. 10.1097/01.prs.0000256049.53562.39.View ArticlePubMedGoogle Scholar
- McCormick LL, Zhang Y, Tootell E: Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol. 1999, 163: 5693-5699.PubMedGoogle Scholar
- Shah M, Foreman DM, Ferguson MW: Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J Cell Sci. 1995, 108 (Pt 3): 985-1002.PubMedGoogle Scholar
- Wu L, Siddiqui A, Morris DE: Transforming growth factor beta 3 (TGF beta 3) accelerates wound healing without alteration of scar prominence. Histologic and competitive reverse-transcription-polymerase chain reaction studies. Arch Surg. 1997, 132: 753-760.View ArticlePubMedGoogle Scholar
- Soo C, Beanes SR, Hu FY: Ontogenetic transition in fetal wound transforming growth factor-beta regulation correlates with collagen organization. Am J Pathol. 2003, 163: 2459-2476.View ArticlePubMedPubMed CentralGoogle Scholar
- Ask K, Bonniaud P, Maass K: Progressive pulmonary fibrosis is mediated by TGF-beta isoform 1 but not TGF-beta3. Int J Biochem Cell Biol. 2008, 40: 484-495. 10.1016/j.biocel.2007.08.016.View ArticlePubMedGoogle Scholar
- Dooley S, Hamzavi J, Ciuclan L: Hepatocyte-specific Smad7 expression attenuates TGF-beta-mediated fibrogenesis and protects against liver damage. Gastroenterology. 2008, 135: 642-659. 10.1053/j.gastro.2008.04.038.View ArticlePubMedGoogle Scholar
- Leask A: Targeting the TGFbeta, endothelin-1 and CCN2 axis to combat fibrosis in scleroderma. Cell Signal. 2008, 20: 1409-1414. 10.1016/j.cellsig.2008.01.006.View ArticlePubMedGoogle Scholar
- Razzaque MS, Ahmed AR: Collagens, collagen-binding heat shock protein 47 and transforming growth factor-beta 1 are induced in cicatricial pemphigoid: possible role(s) in dermal fibrosis. Cytokine. 2002, 17: 311-316. 10.1006/cyto.2002.1020.View ArticlePubMedGoogle Scholar
- Razzaque MS, Foster CS, Ahmed AR: Role of collagen-binding heat shock protein 47 and transforming growth factor-beta1 in conjunctival scarring in ocular cicatricial pemphigoid. Invest Ophthalmol Vis Sci. 2003, 44: 1616-1621. 10.1167/iovs.02-0644.View ArticlePubMedGoogle Scholar
- Uitto J, Perejda AJ, Abergel RP: Altered steady-state ratio of type I/III procollagen mRNAs correlates with selectively increased type I procollagen biosynthesis in cultured keloid? broblasts, Proc. Natl Acad Sci USA. 1985, 82: 5935-5939. 10.1073/pnas.82.17.5935.View ArticleGoogle Scholar
- Zhang LQ, Laato M, Muona P: A fibroblast cell line cultured from a hypertrophic scar displays selective downregulation of collagen gene expression: barely detectable messenger RNA levels of the pro alpha 1(III) chain of type III collagen. Arch Dermatol Res. 1995, 287: 534-538. 10.1007/BF00374072.View ArticlePubMedGoogle Scholar
- Gordon KJ, Blobe GC: Role of transforming growth factor-β superfamily signaling pathways in human disease. Biochimica et Biophysica Acta. 2008, 1782: 197-228.View ArticlePubMedGoogle Scholar
- Hsu M, Peled ZM, Chin GS: Ontogeny of expression of transforming growth factor-beta 1 (TGF-beta 1), TGF-beta. Plast Reconstr Surg. 2001, 107: 1787-1794. 10.1097/00006534-200106000-00023.View ArticlePubMedGoogle Scholar
- Brahmatewari J, Serafini A, Serralta V: The effects of topical transforming growth factor-beta2 and anti-transforming growth factor-beta2,3 on scarring in pigs. J Cutan Med Surg. 2000, 4 (3): 126-131.PubMedGoogle Scholar
- Peiro A, Fernandez CI, Gomar F: Gluteal fibrosis. Journal of Bone and Joint Surgery-American Volume. 1975, 57: 987-990.Google Scholar
- Shen YS: Gluteus maximus contracture. Clin Orthop Relat Res. 1982, 185-188.Google Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2474/11/15/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.